Beta-blockers: urgent aspects
https://doi.org/10.18705/1607-419X-2009-15-4-413-415
Abstract
The paper presents the modern view on beta-blockers that are a heterogeneous group of medicines. Their different features and side-effects should be taken in consideration when negate beta-blockers use. In fact, non-selective beta-blockers have side-effects, in particularly metabolic effects, preventing from their use in patients with metabolic syndrome and type 2 diabetes mellitus. At the same time cardioselective beta-blockers do not influence metabolism and can be prescribed to the mentioned patient groups.
About the Authors
Д. Небиеридзе
ФГУ «Государственный научно-исследовательский центр профилактической медицины Федерального агентства по высокотехнологичной медицинской помощи Росмедтехнологии»
Russian Federation
Russian Federation
D. Nebieridze
State Research Center of Preventive Medicine of Rosmedtechnology
Russian Federation
Russian Federation
References
1. Второй пересмотр рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии // Кардиоваск. терапия и профилактика. - 2004. - Т. 3, № 3, ч. 1. - С. 105-120.
2.
3. Российские рекомендации по диагностике и лечению стабильной стенокардии // Приложение к журн. Кардиоваск. терапия и профилактика. - 2004.
4.
5. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр) // Сердечная недостаточность. - 2006. - Т. 8, № 2. - С. 1-35.
6.
7. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure - an overview of the unconfined randomized drug trials in an epidemiological context // Lancet. - 1990. - Vol. 335. - P. 827-838.
8.
9. Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study // Hypertension. - 1991. - Vol. 17. - P. 570-588.
10.
11. Viskin S., Kitzis I., Lev E. et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice // JACC. - 1995. - Vol. 25. - P. 1327-1332.
12.
13. Berne C., Pollare T., Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors // Diabetes Care. - 1991. - Vol. 14 (suppl. 4). - P. 39-47.
14.
15. Lithell H. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism // Diabetes Care. - 1991. - Vol. 14. - P. 203-209.
16.
17. Reneland R., Alvares E., Andersson P.L. et al. Induction of insulin resistance by beta-blockade but not by ACE-inhibition: long-term treatment with atenolol or trandolapril // J. Hum. Hypertens. - 2000. - Vol. 14. - P. 175-180.
18.
19. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Propranolol or HCTZ alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance // Hypertension. - 1985. - Vol. 7. - P. 1008-1016.
20.
21. The Working Group on Hypertension in diabetes: statement on hypertension in diabetes mellitus. Final report // Arch. Int. Med. - 1987. - Vol. 147. - P. 830-842.
22.
23. Pool P.E., Seagren S.C., Salel A.F. Metabolic consequences of treating hypertension // Am. J. Hypertens. - 1991. - Vol. 4. - P. 494-502.
24.
25. Weidmann P., Feffier C., Saxenhofer H. et al. Serum lipoproteins during treatment with antihypertensive drugs // Drugs. - 1988. - Vol. 35 (suppl. 6). - P. 118-134.
26.
27. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease the international verapamil SR/trandolapril study (INVEST): a randomized controlled trial // JAMA. - 2003. - Vol. 290, № 21. - P. 2805-2816.
28.
29. The ALLHAT Officers and Coordinators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic // JAMA. - 2002. - Vol. 288. - P. 2981-2997.
30.
31. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. - 2002. - Vol. 359. - P. 995-1003.
32.
33. Elliot W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis // Lancet. - 2007. - Vol. 369. - P. 210-207.
34.
35. Beevers D.G. The end of beta-blockers for uncomplicated hypertension? // Lancet. - 2005. - Vol. 366. - P. 1510-1512.
36.
37. Hypertension: management of hypertension in adults in primary care. NICE. / BHS. - 2006. URL: www.nice.org.uk/CGO34.GL
38.
39. Рекомендации по диагностике и лечению артериальной гипертонии (второй пересмотр) // Кардиоваск. терапия и профилактика. - 2008. - № 6 (Приложение).
40.
Review
For citations:
, Nebieridze D. Beta-blockers: urgent aspects . "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(4):413-415. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-4-413-415
Views:
662
Email this article 